Zacks.com on MSN7d
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
Seeking Alpha27d
AstraZeneca, Daiichi win EU backing for breast cancer drug Dato-DXd
Daiichi Sankyo (OTCPK:DSKYF ... Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option for certain cases of breast cancer.
BioSpace1d
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
Breast Cancer Market Sees Rapid Growth — Key Insights And Forecasts Of Different Breast Cancers For The Coming 10 Years | Delveinsight
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
pharmaphorum1d
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...
pharmaphorum24d
Company Profile: Daiichi Sankyo
Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.
Seeking Alpha28d
Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript
Sales of Daiichi Sankyo Espha products are no longer recorded ... milestone payments etc related to the alliance with AstraZeneca and US MRK increased by JPY25.3 billion mainly due to the ...
Hosted on MSN25d
Incoming Daiichi Sankyo CEO shares business roadmap going forward
current COO and incoming CEO of Daiichi Sankyo, talks about the pharmaceutical company's product pipeline, including its cancer treatments, and its global partnerships with AstraZeneca and Merck.
The Lancet2d
Personalised type 2 diabetes therapy in primary care
The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and ...
MedPage Today8d
No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Palbociclib ...
FiercePharma13d
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type.
Business Wire24d
Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail
MUNICH & CAMBRIDGE, England--(BUSINESS WIRE)--A new survey sponsored by Daiichi Sankyo and AstraZeneca reveals that there is a need for more readily available information on breast cancer ...